

INSIDE INFORMATION NOTICE

Sale of shares of Laboratorios Farmacéuticos Rovi, S.A.

Madrid, April 11th, 2022

Bestinver S.V, S.A. (Sociedad Unipersonal) ("**Bestinver**"), in compliance with the provisions of Article 17 of Regulation (EU) No. 596/2014 on market abuse and Article 226 of the revised text of the Securities Market Law, approved by Royal Legislative Decree 4/2015, of October 23, and concordant provisions, hereby notifies the *Comisión Nacional del Mercado de Valores* (the Spanish National Securities Market Commission) of the following inside information:

Bestinver has executed, on behalf of Norbel Inversiones, S.L. (the "**Seller**"), a block trade with a single institutional investor (the "**Buyer**") of 560,690 shares (the "**Shares**") of Laboratorios Farmacéuticos Rovi, S.A., ("**Rovi**"), representing approximately 1% of its share capital.

The sale price amounted to 67.5€ per Share, which represents a discount of approximately 1.1% of the closing price of Rovi's shares in today's session.

Bestinver, as placement entity of the accelerated book building of Rovi's shares communicated to the market on 14 March 2022 by means of an inside information notice number 1362, has agreed to waive for this transaction the 180-day lock up, considering that this is a single sale transaction, with one institutional investor only, based on a reverse enquiry and at a price higher than the placement price.

The waiver of the lock-up provides the Buyer the optionality to acquire an additional 1% of Rovi's share capital, which if agreed, would be subject to market and pricing conditions, and that may be executed on or before 30th June 2022.

With the sale of Shares and provided the option for the additional 1% is exercised, the Seller intends to maintain a majority shareholding position in Rovi, with a 53,17% of Rovi's share capital which, once the shares acquired by the company under the buy-back programs have been redeemed, will represent 55,5%.

Yours faithfully,

Bestinver SV S.A.U.